Targeted treatments to improve stem cell outcome: old and new drugs.

about

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients.Evaluating Treatment Strategies for Spinal Lesions in Multiple Myeloma: A Review of the Literature

P2860

Q33388541-543E6FCF-EA16-4CB9-91FB-A72F9B002823 Q53245450-E4866BFD-CD1D-49E0-94B0-5A522F9D50B8 Q58563417-8484DCE1-BC9D-4DE7-B2C3-233911433262

P2860

Targeted treatments to improve stem cell outcome: old and new drugs.

Item

http://www.wikidata.org/entity/Q36927960

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Targeted treatments to improve stem cell outcome: old and new drugs.

@en

type

Item

label

Targeted treatments to improve stem cell outcome: old and new drugs.

@en

prefLabel

Targeted treatments to improve stem cell outcome: old and new drugs.

@en

P1476

Targeted treatments to improve stem cell outcome: old and new drugs.

@en

P2093

Anderson KC

http://www.w3.org/2001/XMLSchema#string

Breitkreutz I

http://www.w3.org/2001/XMLSchema#string

Raab MS

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.

Antitumor activity of thalidomide in refractory multiple myeloma.

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

P2888

sj.bmt.1705829

P304

1129-1137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1705829

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6072922

http://www.w3.org/2001/XMLSchema#string

P698

17768392

http://www.w3.org/2001/XMLSchema#string

Targeted treatments to improve stem cell outcome: old and new drugs.

about

P2860

P2860

Targeted treatments to improve stem cell outcome: old and new drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698